Investors focused on the Medical space have likely heard of Advaxis (ADXS - Free Report) , but is the stock performing well in comparison to the rest of its sector peers? Let's take a closer look at the stock's year-to-date performance to find out.
Advaxis is one of 833 companies in the Medical group. The Medical group currently sits at #3 within the Zacks Sector Rank. The Zacks Sector Rank gauges the strength of our 16 individual sector groups by measuring the average Zacks Rank of the individual stocks within the groups.
The Zacks Rank emphasizes earnings estimates and estimate revisions to find stocks with improving earnings outlooks. This system has a long record of success, and these stocks tend to be on track to beat the market over the next one to three months. ADXS is currently sporting a Zacks Rank of #1 (Strong Buy).
Over the past three months, the Zacks Consensus Estimate for ADXS's full-year earnings has moved 71.63% higher. This signals that analyst sentiment is improving and the stock's earnings outlook is more positive.
According to our latest data, ADXS has moved about 158.95% on a year-to-date basis. Meanwhile, stocks in the Medical group have gained about 10.44% on average. As we can see, Advaxis is performing better than its sector in the calendar year.
Looking more specifically, ADXS belongs to the Medical - Biomedical and Genetics industry, which includes 344 individual stocks and currently sits at #89 in the Zacks Industry Rank. Stocks in this group have gained about 13.14% so far this year, so ADXS is performing better this group in terms of year-to-date returns.
ADXS will likely be looking to continue its solid performance, so investors interested in Medical stocks should continue to pay close attention to the company.